Home›Clinical trials›Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults

A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help with weight.

Who can join
Adults 18 to 99, have obesity or are overweight, BMI 25+.
What you take
Maridebart Cafraglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 1.8 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor AmgenDrug Maridebart CafraglutideClass OtherSites 42 USEnrollment target 300

What this study is for

Primary condition: Obesity or Overweight.

Full scientific study title: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults.

Who can join

Age18 to 99SexAnyBMI25 or higher

Adults 18 to 99, have obesity or are overweight, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Body Mass Index (BMI) >= 25 at screening.
  • Weight loss of >= 10% on weekly GLP-1 RA.
  • Stable body weight.
  • Stable dose of GLP-1RA.
  • Stable gastrointestinal (GI) tolerability.

Key exclusion criteria

  • Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
  • Previous or planned surgical, endoscopic or device-based treatment for obesity.
  • History of malignancy.
  • Type 1/Type 2 diabetes mellitus (DM).
  • Family or personal history of medullary thyroid cancer.

Where this study is enrolling

This trial has 42 sites across 16 states. Contact a site coordinator directly to start screening.

Alabama1 site
  • Cahaba Research, Inc.
    Pelham, Alabama
Arizona2 sites
  • Arizona Clinical Trials
    Chandler, Arizona
  • Epic Medical Research - Sun City
    Sun City, Arizona
California5 sites
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California
  • Inland Empire Liver Foundation
    Rialto, California
  • Peninsula Research Associates
    Rolling Hills Estates, California
  • Apex Clinical Research
    San Diego, California
  • Southern California Clinical Research
    Santa Ana, California
Florida9 sites
  • University of Florida Department of Medicine
    Gainesville, Florida
  • Aga Clinical Trials
    Hialeah, Florida
  • South Florida Clinical Research
    Margate, Florida
  • New Horizon Research Center
    Miami, Florida
  • Research Institute of South Florida
    Miami, Florida
  • Clinical Neuroscience Solutions
    Orlando, Florida
  • Florida Institute for Clinical Research
    Orlando, Florida
  • Progressive Medical Research
    Port Orange, Florida
  • Charter Research - The Villages
    The Villages, Florida
Georgia3 sites
  • Nsc Research
    Johns Creek, Georgia
  • Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group
    Union City, Georgia
  • North Georgia Clinical Research
    Woodstock, Georgia
Idaho1 site
  • Solaris Clinical Research
    Meridian, Idaho
Illinois1 site
  • Endeavor Health
    Skokie, Illinois
Michigan1 site
  • Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division
    Troy, Michigan
Mississippi1 site
  • Sky Integrative Medical Center
    Ridgeland, Mississippi
Nevada1 site
  • Excel Clinical Research
    Las Vegas, Nevada
New York2 sites
  • Icahn School of Medicine at Mount Sinai
    New York, New York
  • Rochester Clinical Research
    Rochester, New York
North Carolina3 sites
  • Centricity Research Morehead City Specialty
    Morehead City, North Carolina
  • Accellacare of Raleigh
    Raleigh, North Carolina
  • Accellacare Research of Wilmington
    Wilmington, North Carolina
Oklahoma2 sites
  • Epic Medical Research - Oklahoma
    Chickasha, Oklahoma
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma
Pennsylvania1 site
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania
Texas8 sites
  • Epic Medical Research - DeSoto
    DeSoto, Texas
  • South Texas Research Institute
    Edinburg, Texas
  • Biopharma Informatic, LLC
    Houston, Texas
  • Research Physicians Network, LLC
    Houston, Texas
  • Texas Institute of Cardiology
    McKinney, Texas
  • North Hills Medical Research
    North Richland Hills, Texas
  • VIP Trials
    San Antonio, Texas
  • Northwest Houston Heart Center
    Tomball, Texas
Washington1 site
  • Eastside Research Associates Health Research
    Redmond, Washington

Timeline

Started enrolling: 2026-05-11. Expected completion: 2028-02-28. Last updated on ClinicalTrials.gov: 2026-07-02.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.